peer reviewedStatins, the most popular lipid-lowering agents, have proven their efficacy in preventing cardiovascular events in subjects with lower and lower initial plasma cholesterol levels. Besides, the protective effect does not seem to be directly related neither to the degree of the cholesterol reduction nor to the final level of plasma cholesterol level reached under treatment. Such observations suggest that statins may exert vascular protective effects, at least in part, independently of their specific cholesterol-lowering effect (so-called pleiotropic effects). The present paper will discuss the arguments pro and contra the dosage of cholesterolaemia before initiating a therapy with statin and during treatment follow up, both in su...
peer reviewedCardiovascular prevention should only be considered if the treatment reduces the incide...
Atherosclerosis is the most common cause of myocardial infarctions and stroke in Canada and the worl...
peer reviewedInegy, recently launched by Merck Sharp & Dohme and Schering Plough, is a fixed combina...
peer reviewedClinical lipidology has gained its recognition with the publication of numerous clinica...
Statins are essential drugs for the prevention of coronary and cerebral vascular complications. Besi...
peer reviewedStatins, as compared to placebo, have proven their efficacy in reducing cardiovascular ...
peer reviewedStatins are essential drugs for the prevention of coronary artery disease. There is now...
peer reviewedThe IDEAL ("Incremental Decrease in End Points Through Aggressive Lipid Lowering") stud...
peer reviewedRosuvastatin (Crestor) has been recently launched in Belgium by AstraZeneca. This new s...
peer reviewedSUMMARY : High levels of high-sensitivity C-reactive protein (hs-CRP) are an independen...
SummaryBackgroundScreening for and management of dyslipidaemia are crucial in primary and secondary ...
peer reviewedThe "Treating to New Targets" (TNT) trial compared atorvastatin 80 mg (aiming at reduci...
peer reviewedFixed combination atorvastatin-perindopril (Lipercosyl®) for substitution treatment of ...
editorial reviewedPCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) inhibition has proven its in...
peer reviewedThe demography of dyslipidemia has changed towards a more complex atherogenic dyslipide...
peer reviewedCardiovascular prevention should only be considered if the treatment reduces the incide...
Atherosclerosis is the most common cause of myocardial infarctions and stroke in Canada and the worl...
peer reviewedInegy, recently launched by Merck Sharp & Dohme and Schering Plough, is a fixed combina...
peer reviewedClinical lipidology has gained its recognition with the publication of numerous clinica...
Statins are essential drugs for the prevention of coronary and cerebral vascular complications. Besi...
peer reviewedStatins, as compared to placebo, have proven their efficacy in reducing cardiovascular ...
peer reviewedStatins are essential drugs for the prevention of coronary artery disease. There is now...
peer reviewedThe IDEAL ("Incremental Decrease in End Points Through Aggressive Lipid Lowering") stud...
peer reviewedRosuvastatin (Crestor) has been recently launched in Belgium by AstraZeneca. This new s...
peer reviewedSUMMARY : High levels of high-sensitivity C-reactive protein (hs-CRP) are an independen...
SummaryBackgroundScreening for and management of dyslipidaemia are crucial in primary and secondary ...
peer reviewedThe "Treating to New Targets" (TNT) trial compared atorvastatin 80 mg (aiming at reduci...
peer reviewedFixed combination atorvastatin-perindopril (Lipercosyl®) for substitution treatment of ...
editorial reviewedPCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) inhibition has proven its in...
peer reviewedThe demography of dyslipidemia has changed towards a more complex atherogenic dyslipide...
peer reviewedCardiovascular prevention should only be considered if the treatment reduces the incide...
Atherosclerosis is the most common cause of myocardial infarctions and stroke in Canada and the worl...
peer reviewedInegy, recently launched by Merck Sharp & Dohme and Schering Plough, is a fixed combina...